"Brimonidine Tartrate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.
| Descriptor ID |
D000068438
|
| MeSH Number(s) |
D03.633.100.857.070
|
| Concept/Terms |
Brimonidine Tartrate- Brimonidine Tartrate
- Tartrate, Brimonidine
- 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline D-tartrate
UK 14,304-18- UK 14,304-18
- UK 14,304 18
- UK 14,30418
- UK-14,304-18
- UK14,30418
UK 14308- UK 14308
- UK-14,308
- UK 14,308
- UK14,308
AGN 190342- AGN 190342
- 190342, AGN
- AGN-190342
- AGN190342
Brimonidine- Brimonidine
- 5-bromo-6-(imidazolidinylideneamino)quinoxaline
- 5-bromo-6-(imidazolin-2-ylamino)quinoxaline
- Bromoxidine
|
Below are MeSH descriptors whose meaning is more general than "Brimonidine Tartrate".
Below are MeSH descriptors whose meaning is more specific than "Brimonidine Tartrate".
This graph shows the total number of publications written about "Brimonidine Tartrate" by people in this website by year, and whether "Brimonidine Tartrate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 2 | 2 |
| 2000 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 2 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 3 | 3 |
| 2016 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Brimonidine Tartrate" by people in Profiles.
-
Purgert RJ, Meghpara B, Kolomeyer NN. Corneal subepithelial infiltrates associated with brimonidine use. Can J Ophthalmol. 2020 10; 55(5):e172-e174.
-
Bielory L, Schoenberg D. Emerging Therapeutics for Ocular Surface Disease. Curr Allergy Asthma Rep. 2019 02 28; 19(3):16.
-
Cunningham ET, London NJ, Moorthy R, Garg SJ, Zierhut M. Drugs, Inflammation, and the Eye. Ocul Immunol Inflamm. 2016; 24(2):125-7.
-
Fedorchak MV, Conner IP, Medina CA, Wingard JB, Schuman JS, Little SR. 28-day intraocular pressure reduction with a single dose of brimonidine tartrate-loaded microspheres. Exp Eye Res. 2014 Aug; 125:210-6.
-
Feke GT, Bex PJ, Taylor CP, Rhee DJ, Turalba AV, Chen TC, Wand M, Pasquale LR. Effect of brimonidine on retinal vascular autoregulation and short-term visual function in normal tension glaucoma. Am J Ophthalmol. 2014 Jul; 158(1):105-112.e1.
-
Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield LF, Stein-Gold L, Berson D, Zaenglein A. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea. Cutis. 2014 Mar; 93(3):134-8.
-
Feke GT, Rhee DJ, Turalba AV, Pasquale LR. Effects of dorzolamide-timolol and brimonidine-timolol on retinal vascular autoregulation and ocular perfusion pressure in primary open angle glaucoma. J Ocul Pharmacol Ther. 2013 Sep; 29(7):639-45.
-
Spaeth GL, Bernstein P, Caprioli J, Schiffman RM. Control of intraocular pressure and fluctuation with fixed-combination brimonidine-timolol versus brimonidine or timolol monotherapy. Am J Ophthalmol. 2011 Jan; 151(1):93-99.e4.
-
Ooi YH, Oh DJ, Rhee DJ. Analysis of alpha2-adrenergic receptors and effect of brimonidine on matrix metalloproteinases and their inhibitors in human ciliary body. Invest Ophthalmol Vis Sci. 2009 Sep; 50(9):4237-43.
-
Fudemberg SJ, Batiste C, Katz LJ. Efficacy, safety, and current applications of brimonidine. Expert Opin Drug Saf. 2008 Nov; 7(6):795-9.